AIM ImmunoTech WKN: A2PREX ISIN: US00901B1052 Forum: Aktien Thema: Hauptdiskussion

Schorsch wie ist deine Einschätzung, können sie mit der Pipeline und dem cash im nächsten Jahr die Kurve bekommen?

Könnte ne Perle sein

Echt beeindruckend, sollte eigentlich nur ne Frage sein, bis das Ding knallt

...merci...

Aktuell 460 gelistete Patente: https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-K4H3KK-11891 Alle unter altem Namen HEMISPHERx BIOPHARMA 12 klinische Studien unter HEMISPHERx BIOPHARMA https://clinicaltrials.gov/ct2/results?cond=&term=HEMISPHERx+BIOPHARMA&cntry=&state=&city=&dist= 1 Studie unter AIM Immunotech https://clinicaltrials.gov/ct2/results?cond=&term=aim+Immunotech+&cntry=&state=&city=&dist=

Orphan drug designation für: PRODUCT CANDIDATE Ampligen® COUNTRY USA INDICATION CFS/ME Ampligen® COUNTRY USA INDICATION HIV Ampligen® COUNTRY USA INDICATION Metastatic Melanoma Ampligen® COUNTRY USA INDICATION Renal Cell Carcinoma Ampligen® COUNTRY European Union INDICATION Ebola Virus Disease Alferon N Injection® COUNTRY European Union INDICATION MERS

https://aimimmuno.irpass.com/Hemispherx-Secures-Corrections-from-Two-Stock-News-Organizations-Related-to-Their-Inaccurate-Reporti The two stock news organizations, Sagient Research and StreetAccount, both misreported that the company was raising $70 million in an Equity Distribution Agreement when, actually, the company was simply renewing a prior EDA that was related to an ATM and making the requisite SEC filings to raise up to $4.5 million under the new EDA, the maximum permitted at this time. In fact, the ATM has not even been used in six months.

https://aimimmuno.irpass.com/Hemispherx-Biopharma-Issues-Clinical-Update-for-Ampligen-Immuno-oncology-Program

Katalysatoren: Ampligen plus Intron A Ovarian cancer Phase 1 interim data to be presented 1Q 2020 Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 data due around 2Q 2020. Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 interim data due around 2Q 2020 Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 interim data due around 4Q 2020.

Cash: 9,4Mio$ Burnrate: 848k$ finanziert für 13 Monate (bis Q4 2020) MARKET CAP 3,966,703$ SHARES 8,263,964

https://www.benzinga.com/pressreleases/19/11/ac14821175/correction-aim-immunotech-provides-business-update-for-the-third-quarter-of-2019